There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD52


CD52 Molecule Information

Name:CAMPATH-1 antigen
Target Synonym:He5;CAMPATH-1 antigen;CD52;CDW52 ;HE5;CDw52;Cambridge pathology 1 antigen;Human epididymis-specific protein 5;CD_antigen=CD52;Epididymal secretory protein E5
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

CD52 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CD2-H82E8 Human Biotinylated Human CD52 Protein, His,Avitag™
CD2-H525a Human Human CD52 Protein, Fc Tag
CD2-H82F3 Human Biotinylated Human CD52 Protein, Fc,Avitag™

CD52 Molecule Synonym Name

CDW52,HE5,CD52,CAMPATH-1 antigen

CD52 Molecule Background

CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

CD52 References

CD52 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Alemtuzumab GZ-402673; LDP-03 Approved Bayer, Genzyme CAMPATH fda Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) GENZYME 2001-05-07 Chronic lymphocytic leukemia (CLL), Multiple sclerosis (MS) Details

CD52 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Alemtuzumab biosimilar (Hisun Pharm) IND Filing Hisun Pharm Chronic lymphocytic leukemia (CLL) Details
Campath-1G Phase Ⅱ University of Cambridge, GlaxoSmithKline Graft versus host disease, Transplant rejection Details
GZ-402668 GLD-52; GZ-402668 Phase Ⅰ Genzyme Multiple sclerosis (MS) Details
ALLO-647 ALLO-647 Phase Ⅱ Allogene Therapeutics Non-Hodgkin's lymphoma (NHL) Details
Alemtuzumab biosimilar (Zhangjiang Biotechnology) Phase Ⅱ Shanghai Zhangjiang Biotechnology Chronic lymphocytic leukemia (CLL) Details
Recombinant anti-CD52 humanized monoclonal antibody (Hisun Pharm) IND Filing Hisun Pharm Chronic lymphocytic leukemia (CLL) Details

This web search service is supported by Google Inc.